A randomised, double blind placebo controlled study assessing the effect of recombinant human growth hormone (r-hGH) on live birth rates in women who are poor responders undergoing an Invitro Fertilisation(IVF) or Intracytoplasmic Sperm Injection(ICSI) cycle

Trial Profile

A randomised, double blind placebo controlled study assessing the effect of recombinant human growth hormone (r-hGH) on live birth rates in women who are poor responders undergoing an Invitro Fertilisation(IVF) or Intracytoplasmic Sperm Injection(ICSI) cycle

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Recombinant follicle-stimulating hormone (Primary)
  • Indications Infertility
  • Focus Therapeutic Use
  • Acronyms LIGHT
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 12 Jul 2012 Actual initiation date (15 Dec 2009) added as reported by Australian New Zealand Clinical Trials Registry record.
    • 12 Jul 2012 Additional lead trial centre (Genea) added as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top